Aspen Pharmacare, Africas largest pharmaceutical company, led by South African pharma tycoon Stephen Saad, has agreed to sell most of its Asia-Pacific operationsexcluding Chinato Australian private equity firm BGH Capital for A2.37 billion 1.59 billion, a move aimed at reducing debt and freeing up capital as the company recalibrates its business.
Strategic divestment reshapes Aspen footprint
The assets being sold span Hong Kong, Taiwan, Malaysia and the Philippines. Together, they accounted for 18 percent of Aspens revenue and 26 percent of core earnings in the year ended June 30, 2025. Aspen had not planned to divest the businesses but decided to after reviewing an unsolicited proposal from BGH, which focuses on investments in Australia and New Zealand.
